(Q44243674)

1 December 2017

Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports (English)

1 reference

1 December 2017

0 references

1 reference

2

Gary S Goldfield

1 reference

1 December 2017

Ahmed Boachie

1

1 reference

PubMed ID

12474205

1 December 2017

Wendy Spettigue

series ordinal

3

1 reference

1 December 2017

1 January 2003

1 reference

International Journal of Eating Disorders

1 December 2017

1 reference

1 December 2017

33

1 reference

1 December 2017

1

1 reference

1 December 2017

98-103

1 reference

Low discharge weight and outcome in anorexia nervosa

1 December 2017

1 reference

7 January 2021

Mood stabilizer augmentation with olanzapine in acutely manic children

1 reference

7 January 2021

Treatment and outcome of anorexia nervosa

1 reference

7 January 2021

Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa?

1 reference

7 January 2021

Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone

1 reference

7 January 2021

An outcome study of anorexia nervosa in an adolescent unit

1 reference

7 January 2021

Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa

1 reference

7 January 2021

Case reports of olanzapine treatment of anorexia nervosa.

1 reference

7 January 2021

Olanzapine in treatment-resistant bipolar disorder

1 reference

7 January 2021

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.

1 reference

7 January 2021

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

7 January 2021

Percentiles for body mass index in U.S. children 5 to 17 years of age.

1 reference

7 January 2021

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group

1 reference

7 January 2021

Identifiers

DOI

10.1002/EAT.10115

1 reference

1 December 2017

1 reference

PubMed ID

12474205